Welcome to our dedicated page for Paragon 28 news (Ticker: FNA), a resource for investors and traders seeking the latest updates and insights on Paragon 28 stock.
Paragon 28, Inc. (FNA) is a pioneering medical devices company focused exclusively on the orthopedic foot and ankle market. Founded in 2010, the name ‘Paragon 28’ signifies its dedication to this niche, with ‘28’ representing the number of bones in the human foot. The company was started as a small, family-based business and, while it has seen significant growth, it holds steadfast to its original core values.
Paragon 28 is dedicated to advancing the science behind foot and ankle surgery through innovative and high-quality solutions. The company collaborates with global thought leaders to blend various surgical philosophies, resulting in biomechanically and clinically relevant surgical solutions. Their comprehensive product lineup includes plates and plating systems, screws, staples, and nails designed for all major foot and ankle procedures such as ankle, Charcot, fracture fixation, hallux valgus, hammertoe, and flat foot corrections.
With nearly 80 product systems, Paragon 28 aims to meet the specific needs of each patient and procedure, ensuring precise and effective outcomes. The company is also committed to providing excellent customer service through a dedicated and highly trained distribution network, primarily targeting the foot and ankle market.
Operating efficiently to meet the demands of pricing pressures and reimbursement challenges, Paragon 28 generates the majority of its revenue from the United States. The company's relentless focus on innovation and service has led to significant milestones, making it a trusted name in the foot and ankle surgical space.
Zimmer Biomet reported strong Q4 2024 financial results with net sales of $2.023 billion, up 4.3% year-over-year (4.9% constant currency). Full-year net sales reached $7.679 billion, increasing 3.8% (4.8% constant currency).
Q4 net earnings were $239.4 million ($462.4 million adjusted), with diluted EPS of $1.20 ($2.31 adjusted). Full-year net earnings totaled $903.8 million ($1.630 billion adjusted), with diluted EPS of $4.43 ($8.00 adjusted).
The company announced plans to acquire Paragon 28, expanding into the $5 billion foot and ankle segment. Notable achievements include FDA approval for the Oxford® Cementless Partial Knee and OsseoFit™ Stemless Shoulder System. For 2025, the company projects revenue growth of 1.0-3.5% (3.0-5.0% constant currency) and adjusted EPS of $8.15-$8.35.
Zimmer Biomet (NYSE: ZBH) has announced a definitive agreement to acquire Paragon 28 (NYSE: FNA) for $13.00 per share in cash, representing an equity value of approximately $1.1 billion and enterprise value of $1.2 billion. Paragon 28 shareholders will receive a non-tradeable contingent value right (CVR) worth up to $1.00 per share if certain revenue milestones are achieved in fiscal year 2026.
The acquisition expands Zimmer Biomet's presence in the ~$5 billion foot and ankle segment. Paragon 28, established in 2010, offers surgical solutions across major foot and ankle segments. The transaction is expected to immediately accelerate Zimmer Biomet's revenue growth, with Paragon 28's projected 2024 net revenue between $255.9-256.2 million, representing 18.2-18.4% growth.
The deal is anticipated to close in first half of 2025, subject to regulatory approvals and Paragon 28 stockholder approval. It is expected to be approximately 3% dilutive to adjusted EPS in 2025, 1% dilutive in 2026, and accretive within 24 months of closing.
Paragon 28 (NYSE: FNA), a leading medical device company in the foot and ankle orthopedic market, announced its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2024.
For the fourth quarter of 2024, net revenue is expected to range between $71.5 million and $71.8 million, reflecting a growth rate of approximately 18.0% to 18.5% compared to the same period in 2023. For the full year of 2024, net revenue is anticipated to be between $255.9 million and $256.2 million, representing a growth rate of about 18.2% to 18.4% compared to the full year of 2023.
These figures are preliminary and unaudited, subject to adjustments following the completion of quarter-end and year-end closing procedures, and further financial review. Paragon 28's independent registered public accounting firm has not audited, reviewed, or compiled this preliminary financial information.
CEO Albert DaCosta noted that 2024 was a transformative year with significant achievements in growth, innovation, and operational efficiency, positioning the company for sustainable, profitable growth in the future.
Paragon 28 (NYSE: FNA), a specialized medical device company focused on foot and ankle orthopedics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's Chairman and CEO Albert DaCosta, along with CFO & EVP of Supply Chain Operations Chadi Chahine, will deliver a presentation on Monday, January 13, 2025, at 7:30 a.m. Pacific Time / 8:30 a.m. Mountain Time.
Interested parties can access the presentation through a live webcast, and an archived recording will be made available on the investor relations section of Paragon 28's website at ir.paragon28.com.
Paragon 28 (NYSE: FNA), a foot and ankle surgical solutions provider, has appointed Dave Demski as an independent director, expanding its board from eight to nine members. Demski brings over two decades of orthopedic executive leadership experience, having most recently served as President and CEO of Globus Medical from 2017 to 2022. His background includes roles as CFO, COO, and President of Emerging Technologies at Globus Medical. Currently, he serves on the board of Alphatec Spine and previously served on Axonics' board until its acquisition by Boston Scientific in 2024. Demski holds a B.S. in Business Administration from the University of Michigan and an MBA from Stanford.
Cohen Milstein has announced a securities class action lawsuit against Paragon 28 (NYSE:FNA), a medical device company, regarding alleged false and misleading statements about financial statements and internal controls. The lawsuit covers investors who purchased shares between May 5, 2023, and September 20, 2024. Investors who suffered significant losses during this period have until November 29, 2024, to request appointment as lead plaintiff. The complaint, filed in the U.S. District Court for the District of Colorado, alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by current and former officers.
Paragon 28 (NYSE: FNA), a specialized medical device company focusing on foot and ankle orthopedics, has announced its participation in the 36th Annual Piper Sandler Healthcare Conference. Chairman and CEO Albert DaCosta and CFO Chadi Chahine will engage in a fireside chat on Tuesday, December 3, 2024, at 8:30 a.m. Eastern Time. The presentation will be accessible via live webcast and archived recording on the company's investor relations website at ir.paragon28.com.
A class action securities lawsuit has been filed against Paragon 28 (NYSE:FNA), a medical device company, in the U.S. District Court for the District of Colorado. The lawsuit alleges that the company and certain officers made false and misleading statements regarding financial statements and internal controls between May 5, 2023 and September 20, 2024. Cohen Milstein Sellers & Toll PLLC is urging affected shareholders who suffered significant losses during this period to contact them by November 29, 2024 to potentially serve as lead plaintiff. Investors are not required to file as lead plaintiff to participate in any potential recovery.
Paragon 28, a medical device company in the foot and ankle orthopedic market, reported its Q3 2024 financial results and raised its 2024 net revenue guidance. The company recorded global net revenue of $62.3 million, marking 18.1% reported growth compared to the prior year. U.S. net revenue was $51.2 million, a 14.8% increase, while international net revenue was $11.2 million, up 35.7%. Despite a net loss of $12.3 million, this was an improvement from the $11.2 million loss in Q3 2023. Gross margin decreased to 74.1% from 77.4%. Operating expenses rose 6.3% to $54.6 million. Adjusted EBITDA turned positive to $0.4 million. Free Cash Flow improved by 69.5% year-over-year. The company raised its 2024 net revenue guidance to $252-$256 million, representing 16.5%-18.3% growth.
Rigrodsky Law has initiated an investigation into Paragon 28 (NYSE:FNA) regarding potential claims against its officers and directors. The investigation focuses on whether the company and its leadership issued materially misleading information or failed to disclose material information to investors concerning financial outlook and internal controls over financial reporting. The investigation covers shareholders who acquired Paragon shares on or before May 5, 2023. Affected shareholders can learn more about their rights at no cost through Rigrodsky Law's website or by contacting their representative.
FAQ
What is the current stock price of Paragon 28 (FNA)?
What is the market cap of Paragon 28 (FNA)?
What does Paragon 28, Inc. specialize in?
When was Paragon 28, Inc. founded?
What is the significance of the name 'Paragon 28'?
What types of products does Paragon 28 offer?
How many product systems does Paragon 28 have?
Where does Paragon 28 generate the majority of its revenue?
What is Paragon 28’s approach to innovation?
What is Paragon 28’s commitment to customer service?
How does Paragon 28 address pricing pressures and reimbursement challenges?
What recent achievements has Paragon 28 made?
